Kopfbereich
Logo
Login
AOP Orphan Contact
AOP Orphan worldwide
Wilhelminenstraße 91/IIf
1160 Vienna, Austria
office(at)aoporphan.com
Press release
Press room
This section of our site provides general information about AOP Orphan. We will be happy to answer any questions or comments you may have:
T. +43 1 503 72 44-24
F. +43 1 503 72 44-5
E-Mail: publicaffairs@aoporphan.com
Bioprojet Pharma SAS and AOP Orphan Pharmaceuticals AG (AOP Orphan) entered a distribution agreement for Wakix®The covered territory includes mainly Central and Northern European countriesWakix® is approved for treatment of...
AOP Orphan supports the Christian Doppler Laboratory for Iron Metabolism and Anemia Research at the Medical University of Innsbruck, Austria, opening on January 31st, 2018. To read the full press release in German, please click...
High rates and durable Clinical and Hematological response were achieved with Ropeginterferon alfa-2b at 24 months of treatment The disease modifying capability of Ropeginterferon alfa-2b was further supported by 24 month...
03.10.2017:
AOP In Press: UK CPA in Practice
PDF to download
AOP Orphan Pharmaceuticals AG announced today that it has acquired Selisistat, a highly selective SIRT1 inhibitor, which in experimental studies has previously shown potential disease modifying properties in a number of...
31.08.2017:
Austria as a Research & Development base
An interview with Dr Rudolf Widmann, CEO and Dr Christoph Klade, CSO about the current status of Vienna, Austria as a Research & Development base, its specifics, hurdles and chances, which was published recently in...
Cancer Drug News 733
weiter zu "AOP in Press: "New Therapies To Struggle Against Established Hematology""
23.06.2017:
AOP and PharmaEssentia announce latest clinical results for Ropeginterferon alfa-2b in Polycythemia Vera
Long-term maintenance treatment of Polycythemia Vera (PV) patients with Ropeginterferon alfa-2b administered every 4 weeks is feasible, efficacious and well toleratedHome self-administration of individual doses with a pen is well...
AOP Orphan Pharmaceuticals AG (AOP Orphan) today announced that RAPIBLOC® (Rapibloc, 300 mg powder for solution for infusion) will as of June 19th be first commercialized by its distribution partner Amomed Pharma GmbH (Amomed)...
16.05.2017:
Rare Diseases: AOP Orphan Pharmaceuticals AG invests in sustainable Research & Development
An interview with Dr Rudolf Widmann, CEO and Dr Christoph Klade, CSO about AOP Orphan’s commitment to sustainable innovation for the benefit of patients with rare diseases and Austria as a research location was published recently...
The internationally active, Vienna-based pharmaceutical company AOP Orphan, which specializes in rare diseases, has appointed Miroslaw Jan Lubecki MD, MBA to join the management team as Chief of Commercial Operations.
weiter zu "Miroslaw Jan Lubecki – newly appointed Chief of Commercial Operations "
EMA started the centralized marketing authorization procedure for Ropeginterferon alfa-2b for treatment of Polycythemia Vera (PV) on Feb 23rd 2017. Ropeginterferon alfa-2b is a novel mono-pegylated interferon with an improved...
At 12 months of treatment ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) in Complete Hematologic Response (CHR) PROUD-PV demonstrated a significantly better safety and tolerability profile of ropeginterferon...
Highlights: Ultra-short acting and highly cardio-selective beta blocker Rapibloc® (Landiolol) receives regulatory approval in Europe.Rapibloc® (Landiolol) allows rapid control of heart rate with a straightforward dosing scheme...
04.04.2016:
Roland Bindeus moves from Baxalta to AOP Orphan – new Head of the Hematology & Oncology Business Unit
Dr Roland Bindeus (38) took control of the Hematology & Oncology Business Unit at the Austrian pioneer of rare diseases, AOP Orphan, at the beginning of April. The biochemist was most recently the general manager of Baxalta...
The internationally active, Vienna-based pharmaceutical company AOP Orphan, which specialises in rare diseases, has appointed Suzie McFadzean to join the management team as Chief of Commercial Operations. British-born Suzie...
weiter zu "Suzie McFadzean – new Chief of Commercial Operations "
19.06.2015:
AOP Orphan strengthens core CNS specialty business with high promise in movement disorder treatments
AOP Orphan Pharmaceuticals AG announced today the regulatory submission of Tetrabenazine for the treatment of tardive dyskinesia in a DCP (decentralized procedure) for several European countries with UK being reference member...
As an easy-to-use and highly reliable inhalation powder, the antipsychotic ADASUVE® has revolutionized the treatment of agitation in patients suffering from schizophrenia or bipolar disorder. This was also confirmed by experts...
weiter zu "Innovative antipsychotic ADASUVE® to benefit even more patients"
30.04.2015:
Homozygous Familial Hypercholesterolaemia
The Austrian pharmaceutical pioneer AOP Orphan is now bringing Lojuxta® (lomitapide) Capsules to the Austrian market
Today AOP Orphan Pharmaceuticals AG, Austria, and Rigi Healthcare AG, Switzerland, announced the creation of Rigi Orphan Inc, USA. The new company will focus on the development, in-licensing and commercialization of...
weiter zu "AOP Orphan and Rigi Healthcare start Rigi Orphan Inc., USA "
INDIANAPOLIS, IN — CONFLUENCE PHARMACEUTICALS and AOP Orphan Pharmaceuticals AG (“AOP”), announced today they have signed a definitive agreement to co-develop and market Confluence’s lead asset, a product for the treatment of...
Highlights: AOP Orphan announces completion of recruitment of its pivotal phase III trial PROUD-PV (www.proud-pv.com) to support global licensure of Ropeginterferon alfa 2b - Ropeginterferon alfa 2b is a novel, long-acting,...
10.12.2014:
AOP Orphan to be commercialization partner for Canadian pharmaceutical specialist Cardiome
The Austrian pharmaceutical company AOP Orphan, which specialises in rare diseases and innovative therapies, will in future market the two special preparations by the highly innovative, publicly listed company Cardiome Pharma...
The pharmaceutical company AOP Orphan, a European pioneer in the field of rare diseases, is expanding its sales area for the special preparation Thromboreductin® to include the large Russian market. This means that the drug,...
weiter zu "AOP Orphan brings Thromboreductin® to the Russian market"
25.08.2014:
AOP Orphan to market the innovative antiarrhythmic drug BRINAVESS® exclusively in Central Europe
The Austrian pharmaceutical company AOP Orphan, which specialises in rare diseases and innovative therapies, will in future market the antiarrhythmic drug BRINAVESS®, developed by Cardiome Pharma Corp., Canada, in Central Europe....
02.05.2014:
Internationally renowned pharmaceutical expert Hans Peter Hasler strengthens AOP Orphan Supervisory Board
The Austrian pharmaceutical company AOP Orphan is a European pioneer in the field of rare diseases. Industry expert Hans Peter Hasler (58) joined AOP Orphan’s Supervisory Board at the beginning of the year. The Swiss native...
AOP Orphan and Ferrer Internacional are expanding their long-standing partnership to include the marketing of the anti-psychotic drug Adasuve® (Staccato® Loxapine) in Central and Eastern Europe.
weiter zu "Partnership between AOP Orphan and Ferrer: Joint marketing of Adasuve® in CEE"
In order to add impetus to the rapid expansion of recent years, the Austrian pharmaceutical company AOP Orphan is strengthening its management team.
weiter zu "AOP Orphan Expands and Enlarges the Management Team"
AOP Orphan announces progress of pan-European phase III trial PROUD-PV to support European Marketing Authorization of AOP2014/P1101, a next-generation, mono-pegylated Interferon alpha 2b.
AOP Orphan Pharmaceuticals has been awarded the exclusive distributions rights for Brinavess® (vernakalant) by Cardiome Pharma Corporation for most Central and Eastern European countries, as well as for Switzerland and Austria....
weiter zu "AOP Orphan expands its range of special cardiovascular preparations"
15.06.2013:
Andreas Steiner – New CFO at AOP Orphan
The Austrian pharmaceutical company AOP Orphan – a European pioneer in the field of rare diseases – has brought on board a health sector expert, Andreas Steiner (53), with many years of management experience to become CFO.
Non-inferiority of anagrelide compared to hydroxyurea in WHO-essential ET. (Prepublished online, Blood, Jan. 11, 2013)
weiter zu "Essential Thrombocythemia (ET) – Convincing data of ANAHYDRET study now published "
AOP Orphan Pharmaceuticals AG (AOP Orphan) today announced that based on promising phase II data it will initiate a phase III trial to support European Marketing Authorization of a novel mono-pegylated Interferon alpha 2b...
30.05.2012:
Video "Loser in the gene roulette"
A documentary on living with rare diseases; by Edith Bachkönig (currently available in German only)
At AOP Orphan are European pioneers in the field of Orphan Diseases. We research, develop, produce, and distribute innovative solutions for Rare Diseases worldwide.
weiter zu "AOP Orphan - A European Pioneer in the field of Rare Diseases"
30.05.2012:
Meet Dr. Christoph Klade, the newest member of the Rare Disease specialist AOP Orphan’s management team
With the arrival of Dr. Christoph Klade (43), we are pleased to welcome a renowned expert to our management team. He will be in charge of research and development activities sector here at AOP Orphan. AOP Orphan is an Austrian...
Contact
AOP Orphan Pharmaceuticals AG
Wilhelminenstraße 91/IIf
1160 Vienna
T +43 1 503 72 44-24
F +43 1 503 72 44-5
E-mail: publicaffairs@aoporphan.com